Non-interventional Study of Cabozantinib in Adults With Advanced Renal Cell Carcinoma
Launched by IPSEN · Jan 26, 2018
Trial Information
Current as of May 14, 2025
Completed
Keywords
ClinConnect Summary
The study will follow the real-life management of patients in clinical practice. Visits will take place according to the study site's clinical practice. Cabozantinib is to be administered as directed by the investigator according to the study site's usual clinical practice and the Cabometyx™ Summary of Product Characteristics (SmPC).
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥18 years old
- • Has a diagnosis of advanced RCC
- • Has received at least one prior VEGF-targeted therapy
- • For whom the treating physician has decided to start treatment with cabozantinib tablets prior to inclusion
- • No previous exposure to cabozantinib prior to inclusion
- • Not concurrently involved in an interventional study
- • Consents to participate in this noninterventional study
- Exclusion Criteria:
- • There are no exclusion criteria for this study.
About Ipsen
Ipsen is a global biopharmaceutical group dedicated to innovation and specialty care, focusing on the discovery, development, and commercialization of transformative medicines for patients with serious diseases. With a strong emphasis on oncology, neuroscience, and rare diseases, Ipsen leverages cutting-edge research and advanced technologies to deliver high-quality therapies that address unmet medical needs. Committed to scientific excellence and ethical practices, Ipsen collaborates with healthcare professionals and stakeholders to drive patient-centered solutions and improve health outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Athens, , Greece
Barcelona, , Spain
Madrid, , Spain
Barcelona, , Spain
Oostende, , Belgium
Bonheiden, , Belgium
Hamburg, , Germany
Madrid, , Spain
Lugo, , Spain
Preston, , United Kingdom
Breda, , Netherlands
Napoli, , Italy
Grenoble, , France
Créteil, , France
Canterbury, , United Kingdom
Brasschaat, , Belgium
Barcelona, , Spain
Angers, , France
Derby, , United Kingdom
Milano, , Italy
Girona, , Spain
Edegem, , Belgium
Athens, , Greece
Münster, , Germany
Besançon, , France
Pamplona, , Spain
Strasbourg, , France
Parma, , Italy
Hasselt, , Belgium
Palma De Mallorca, , Spain
Salzburg, , Austria
Sabadell, , Spain
León, , Spain
Trento, , Italy
Caen, , France
Barcelona, , Spain
Verona, , Italy
Modena, , Italy
Bordeaux, , France
Linz, , Austria
Liberec, , Czechia
Praha 4, , Czechia
Praha, , Czechia
Praha, , Czechia
Bayonne, , France
Cabestany, , France
Limoges, , France
Paris, , France
Quimper, , France
Reims, , France
Saint Priest En Jarez, , France
Strasbourg, , France
Tours, , France
Berlin, , Germany
Eisenach, , Germany
Frankfurt, , Germany
Halle, , Germany
Hamburg, , Germany
München, , Germany
Saalfeld, , Germany
Tuebingen, , Germany
Ulm, , Germany
Athens, , Greece
Athens, , Greece
Ioánnina, , Greece
Thessaloníki, , Greece
Thessaloníki, , Greece
Bologna, , Italy
Napoli, , Italy
Padova, , Italy
Pavia, , Italy
Reggio Emilia, , Italy
Roma, , Italy
Rome, , Italy
Vicenza, , Italy
Deventer, , Netherlands
Leidschendam, , Netherlands
Rotterdam, , Netherlands
Bydgoszcz, , Poland
Poznań, , Poland
Warsaw, , Poland
Warsaw, , Poland
Wrocław, , Poland
Murcia, , Spain
Málaga, , Spain
Oviedo, , Spain
Santiago De Compostela, , Spain
Vigo, , Spain
Zaragoza, , Spain
Newcastle, , United Kingdom
Northwood, , United Kingdom
Slough, , United Kingdom
Patients applied
Trial Officials
Ipsen Medical Director
Study Director
Ipsen
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials